
### Accessing the FluSurver in GISAID

### Please send questions and feedback to: flusurver@gisaid.org

The FluSurver team is located in Singapore and our working day for fast replies may be shifted depending on your local time zone.



*First steps:* find, select and add isolates to analyze from the EpiFlu<sup>™</sup> database



Select "FluSurver"

*Next steps:* Select proteins to analyze[1], e.g. HA, then click on continue [2], wait for submission form to load and then click "Analyze with FluSurver" [3].





#### Important usage notes:

Note: unless one

wants to compare

reference strain.

option can be left

at default which

is an automatic

detection of the

closest reference.

the drop-down

to a specific

selected

The main application scenario for FluSurver is to highlight phenotypically or epidemiologically interesting candidate mutations for further research and should ideally be combined with experimental testing and verification of any predicted phenotypes. Importantly, any direct diagnostic use, assumed severity or recommendation on patient treatment should not be based solely on these computational predictions. Our curated reference sequences used for annotation transfer of equivalent truttations are mainly comprised of strains that recently infected humans. Therefore, the usage scenario that will give the most fruitful and reliable results are current surveillance sequences with very close relation to used vaccine strains, including some candidates for avian flu and novel reassortant swine flu H302v

#### Please take a look at the Frequently Asked Questions and Tutorial if you are new to FluSurver.

#### Loaded protein sequences of your selected isolates for FluSurver analysis

>HA\_A/Shanghai/2/2013\_138738

NMTGILVFALIAIIPTNADKICGHHAVSNGTKVNTLTERGVEV/NATETVERTNIPRICSKGKTVDLGQGGLGTITGFPQCDGFLEFSADLIIERREGSDVCYPGKFVNE EALRQILRESGGIDKEAMGFTYSGIRTNGATSACRSSGSFYAEMKNLLSNTDNAAFPQMTKSYKNTRKSPALIVNGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVSPF GAFFQVNGLSGRIDFHWLENNPNDTVTFSNGAFIAPDRASFLRGKSMGIQSGVQDALCEGDCYHSGGTIISNLFFQNUDSRAVGKCPRVYQRSLLLATGKKIVPEIPKGR GLFGAIAGFIENGWEGLIDGWYGFRHQNAGGEGTAADVKSTQSAIDQITGKLNRLIEKTNQQFELIDKFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADS MUCKLYEKKQLERAMEEDDTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMRCTICI >H\_A/Anhu1/1/2013\_138739 MNTQILVFALIAIIPTNADKICGHHAVSNGTKVNTLTERGVEVVNATETVERTNIPRICSKGKTVDLGQGLLGTITGPPQCDQFLEFSADLITERGBGDVCYPGKFVNE ELLRQILRESGGIDKEAMGTYSGIKTNGTSKCRSGSSYVQSFVEVENTENTDNAAFFQMTKSYKNTRKSPLIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSF

GARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRVVKQRSLLLATGMKNVPEIPKGR

Please select the reference strain(s) to compare to:

Automatic detection of closest reference (larger selection of streins, not always full genomes, NOT SUITED to judge reassortment)


# Clear list Continue

Warning: In the current EpiFlu 1.0 version, there can be a server time-out if too many sequences are selected, <20 sequences for analysis should work fine.

### EpiFlu<sup>™</sup> 2.0 – In near Future

Browse > Upload		Work	set Management 🛛 🕨 Ad	ministration	Registered Users	
rsonal Worksheet						
us Name				Q		
Delete Entry	Clear List 👷 Selec	t All 🔆 De	select All			
-	Name	Segme	nt Segment accession #	Length	*	Export selected
A/chicken/77/Jiangxi/20	014	NS	EPI1880	890	/9	Direct Number of de
A/chicken/77/Jiangxi/20	014	PB1	EPI1874	2274	<u></u>	Blast Nucleotide
A/chicken/77/Jiangxi/20		HA	EPI1876	1686	<b>(</b>	Blast Protein
Archicken/77/Jiangxi/20		NP	EPI1877	1501		Didot i Totelli
A/chicken/77/Jiangxi/20		NA	EPI1878	1413		Analyze with FluSurver
A/chicken/77/Jiangxi/20	<u>014</u>	PB2	EPI1873	2280		
A/duck/Jiangxi/95/2014	-	М	EPI1887	982		Align Sequences
A/duck/Jiangxi/95/2014		PA	EPI1883	2151		11: <b>T</b>
A/duck/Jiangxi/95/2014		NS	EPI1888	823		View Tree
A/duck/Jiangxi/95/2014		HA	EPI1884	1704		
A/duck/Jiangxi/95/2014		NP	EPI1885	1497		
A/duck/Jiangxi/95/2014		PB1	EPI1882	2274		
A/duck/Jiangxi/95/2014		PB2	EPI1881	2280		
A/duck/Jiangxi/95/2014		NA	EPI1886	1380		
A/Galicia/1786/2014		HA	EPI1907	1040	Olicitation	
A/Hong Kong/308/2014		PB2	EPI498034	2280	Slight d	change in
A/Hong Kong/308/2014	<u>4</u>	NA	EPI498036	1401	-	
A/Hong Kong/308/2014	<u>4</u>	PB1 EPI498035		2274	appear	ance of
Allong Kong/308/2014	<u>1</u>	PA	EPI498033	2151		
A/Hong Kong/308/201	<u>1</u>	M	EPI498032	982	menu c	options in


4



For each of the query sequences, there are six columns of information generated in the result summary page. From here, users may proceed to look at the query sequence's alignment to the reference strain, get more information on each mutation, generate a structural view of all the mutations in the query sequence ("show in structure") or view a summary of the mutations in a table to download (at end of results).

More details on browsing the results further can be found online at: <a href="http://flusurver.bii.a-star.edu.sg/help/tutorialpage.html#part2">http://flusurver.bii.a-star.edu.sg/help/tutorialpage.html#part2</a>





### Troubleshooting

- I cannot see the structural view!
  - The structural view uses a free Java program called Jmol which requires:
    - a recent version of the free Java Runtime Environment to be installed (<u>http://java.com/en/download/</u>)
    - accepting the security certificate when prompted.
    - If needed, add "http://mendel.bii.astar.edu.sg" and "http://flusurver.bii.astar.edu.sg" to list of trusted sites in the Java configure settings as shown on the right (We have protected the code of the Jmol version used on our server so it cannot be modified by any unauthorized third parties)

#### Steps to Add URLs to the Exception Site list

- Go to the Java Control Panel (On Windows Click Start and then Configure Java)
- Click on the Security tab
- Click on the Edit Site List button
- Click Add in the Exception Site List window

prompts.		wed to run after the appr	opriate secu
Location			
http://www.example.com	h		
		Add	<u>B</u> er
FILE and HTTP protocols a	a second dama di a secondati se dal		

· Click in the empty field under the Location field to enter the URL

Example: http://www.example.com (URL should begin with http:// or https://)

- Answers to more frequently asked questions: <u>http://flusurver.bii.a-star.edu.sg/help/faq.html</u>
- If there are any access problems via GISAID and urgent analysis is needed, you can also use our general site (<u>http://flusurver.bii.a-star.edu.sg/</u>) but this version does not include statistics of GISAID sequences!



The main application scenario for FluSurver is to highlight phenotypically or epidemiologically interesting candidate mutations for further research and should ideally be combined with experimental testing and verification of any predicted phenotypes. Importantly, any direct diagnostic use, assumed severity or recommendation on patient treatment should not be based solely on these computational predictions. Our curated reference sequences used for annotation transfer of equivalent mutations are mainly comprised of strains that recently infected humans. Therefore, the usage scenario that will give the most fruitful and reliable results are current surveillance sequences with very close relation to used vaccine strains, including some candidates for avian flu and novel reassortant swine flu H3N2v. Please take a look at the Frequently Asked Questions and Tutorial if you are new to FluSurver. There is also a special note for using FluSurver results in publications.

Back to Reference Selection

Result for comparison with reference selection: auto

13 0.97872 G F B A T · · gi|316986112|gb|ADU76312.1| neuraminidase [Influenza A virus (A/England/00380009/2009(H1N1))]gi|316986114|gb|ADU76313.1| neu

14 0.97872 GFBAT · · gi[295147036|gb]ADF80503.1| neuraminidase [Influenza A virus (A/Seoul/1870/2009(H1N1))]

04006214b3183824401 11

15 0.97872 GFBAT ··· qi | 307071034 | gb | ADN24718.1 | neuraminidase, partial [Influenza A virus (A/Canada-AB/RV2828/2009(H1N1))]

anomini dos

Rank Score

3 4

5 0.97872

6

8 0 0.97872

10 0.97872


1.0 2

0.97872


Best reference hit % AA identity List of mutations Query % length coverage # mutations V106I, N248D, H275Y show in structure NA A/California/07/2009(H1N1) A/Singapore/GN285/2009(H1N1) 99.360 100.000 3 NA drug sensitivity positions: find closest related sequences 26, 0, 1 Reduced sensitivity or resistance! Right-click here to save/download mutation report table for archiving or import to Excel Back to Reference Selection 🖹 Length: 469 🔍 Views: Plain | Jalview | Raw 🔥 Downloads: FASTA | MAFFT | Raw 🕜 Params: internal, NCBI NR-24070523 sequer Tachyon 11364 hits 🗈 Databases: 💿 All 🔘 PDB 🔘 RefSeg 🔘 SwissProt/UniProtKB 😓 Limit: 💿 250 🔘 1000 🔘 None Hit Seg  $\bigtriangledown$  Filter: G F B A T · · gi|251748198|gb|ACT10319.1| neuraminidase [Influenza A virus (A/Hong Kong/2369/2009(H1N1))]gi|254548844|gb|ACT67256.1| neura 0.9914 GFBAT •• gi|300117086|gb|ADJ67981.1| neuraminidase, partial [Influenza A virus (A/Perth/262/2009(H1N1))] 0.98718 G F BAT gi|326320245|gb|ADZ53143.1| neuraminidase [Influenza A virus (A/Hong Kong/FFD/2009(H1N1))] 0.98294 GFBAT · · gi/291219999/gb/ADD84685.1/ neuraminidase [Influenza A virus (A/Mexico/InDRE797/2010(H1N1))] GFBAT · · gi|251833646|gb|ACT22016.1| neuraminidase [Influenza A virus (A/Osaka/180/2009(H1N1))] 0.97872 GFBAT · · gi|294544923|gb|ADF10109.1| neuraminidase [Influenza A virus (A/Ontario/25913/2009(H1N1))]gi|307071058|gb|ADN24730.1| neuraminidase [Influenza A virus (A/Ontario/25913/2009(H1N1))]gi|307071058|gb|ADN24730.2| neuraminidase [Influenza A virus (A/Ontario/25913/2009(H1N1))]gi|ADN24730.2| neuraminidase [Influenza A virus (A/ONTARio/25913/2009(H1N1)]]gi|ADN24730.2| neuraminidase [Influenza A virus (A/ONTARio/25 Find closest reference G F B A T · · gi|294544441|gb|ADF10049.1| neuraminidase [Influenza A virus (A/Ontario/10016/2009(H1N1))]gi|294544523|gb|ADF10059.1| neuram 0.97872 GFBAT · · gi|299781814|gb|ADJ40477.1| neuraminidase [Influenza A virus (A/Netherlands/2445b/2009(H1N1))] GFBAT · · gi|325451706|gb|ADZ13521.1| neuraminidase [Influenza A virus (A/Lyon/48.49/2009(H1N1))] strain and database hits! GFBAT · · gi|294611208|gb|ADF27356.1| neuraminidase [Influenza A virus (A/Taiwan/6663/2009(H1N1))] 11 0.97872 GFBAT · gi 326320207 gb ADZ53124.1 | neuraminidase [Influenza A virus (A/Hong Kong/23369/2009(H1N1))] 12 0.97872 GFBAT · · gi|425786025|gb|AFX96841.1| neuraminidase [Influenza A virus (А/Viet Nam/12032005/2009(HIN1))]




The main application scenario for FluSurver is to highlight phenotypically or epidemiologically interesting candidate mutations for further research and should ideally be combined with experimental testing and verification of any predicted phenotypes. Importantly, any direct diagnostic use, assumed severity or recommendation on patient treatment should not be based solely on these computational predictions. Our curated reference sequences used for annotation transfer of equivalent mutations are mainly comprised of strains that recently infected humans. Therefore, the usage scenario that will give the most fruitful and reliable results are current surveillance sequences with very close relation to used vaccine strains, including some candidates for avian flu and novel reassortant swine flu H3N2v. Please take a look at the Frequently Asked Questions and Tutorial if you are new to FluSurver. There is also a <u>special note for using FluSurver results in publications</u>.





Color	Interest level	Remarks	Surver							
Black	0 (least significant)	No known effects	isting candidate mutations for further research and should ideally be combined with experimental testing y or recommendation on patient treatment should not be based solely on these computational predictions. uprised of strains that recently infected humans. Therefore, the usage scenario that will give the most used vaccine strains, including some candidates for avian flu and novel reassortant swine flu							
Green	0	Common	new to FluSurver. There is also a <u>special note for using FluSurver results in publications</u> .							
Blue	1	At site of interaction	entity % length coverage # mutations List of mutations							
Orange	2	At site known to involved in drug- binding, alter host- specificity.	V106I. N248D. H275Y show in structure    i0  100.000    3  NA drug sensitivity positions: 26.0.1 Reduced sensitivity or resistance!    in report table for archiving or import to Excel							
Red	<b>3</b> (most significant)	At site known to alter virulence, cause drug resistance, reverses premature STOP codon in PB1-F2.	Singapore ce (INMEGEN), Mexico Check list of mutations!							




Click on mutation of interest for details!









### Mutation frequency pattern highlights relevant changes





Frequency of mutation over time



New H275Y permissive mutations Hurt *et al.* J Infect Dis. 2012 Jul 15;206(2):148-57. Butler *et al.* PLoS Pathog. 2014 Apr 3;10(4):e1004065.

Change in pH-dependency of fusion Maurer-Stroh *et al.* PLoS Curr. 2010 Jun 1;2:RRN1162. Cotter *et al.* PLoS Pathog. 2014 Jan;10(1):e1003831.

#### Example H1N1pdm in FluSurver

Country	Strain	<u>PB2</u>	<u>PB1</u>	PB1- F2	PA	HA	NP	NA	<u>M1</u>	<u>M2</u>	<u>N S1</u>	<u>N S2</u>	Date of collection(YYYYMMDD)
Taiwan	(A/Taiwan/7338/2009(H1N1))	-	-	-	-	A26T P100S P200S S220T I338V E391K	-	- V106I N248D H275Y		-	-	-	20091105
Japan	(A/Kurume/R8/2010(H1N1))		-	-	-	-		V53A V80M S82P V106I N248D H275Y Y282H		-	-	-	20100118
South Korea	(A/Daejeon/1871/2009(H1N1))	-	-	-	-	K39R N73S P100S S145P G172E P200S S220T I338V		A86T V106I I117M N248D H275Y	-		-	-	20091215
United Kingdom	(A/England/94840152/2009(H1N1))	-	-	-	-	P100S P200S S220T I338V		V106I N248D H275Y E462K	-	-	-	-	20091119
Japan	(A/Kurume/N8/2010(H1N1))	-	-	-	-	-		V80M S82P V106I N248D H275Y	-	-	-	-	20100118
United Kingdom	(A/England/00380015/2009(H1N1))		-	-	-	P100S P200S S220T I338V	-	V108I N248D H275Y E482K	-	-	-	-	20091117
USA	(A/California/21/2012(H1N1))	-	-	-	-	S86T P100S K136N S160G P200S S202T A214T S220T D239G N277D 1338V F347L E391K S468N V537A		A20V G41R N44S V108I V241I N248D H275Y N389K		\$13N	-	-	20120220
Viet Nam	(A/Viet Nam/835/2009(H1N1))			-	P224S	P100S P200S S220T I338V	V100I	V106I N248D H275Y			L115F I123V		20090727
Mexico	(A/Mexico/InDRE3354/2012(H1N1))	-	-	-	-	S86T P100S S160G P200S S202T A214T S220T N277D I338V E391K S468N V537A		G41R N44S S95I V106I V241I N248D H275Y N389K	-	-	-	-	20120208
Japan	(A/Kurume/N1/2010(H1N1))	-	-	-	-	-	-	V80M S82P V106I N248D H275Y	-	-	-	-	20100118
USA	(A/Bethesda/NIH108- D14/2009(H1N1))	R591Q	K738G	-	V14I P224S K716Q	A15T P100S P200S S220T I338V E391K F432L		V100I V270I V108I N248D H275Y V444I			1123V		20091105
Japan	(A/Kurume/L19/2010(H1N1))	-	-	-	-	-	-	V80M S82P V106I N248D H275Y	-	-	-	-	20100118
China	(A/Haishu/SWL110/2010(H1N1))		-	-	-	P100S S179N P200S S220T I338V	-	V108I N248D H275Y		-	-	-	20100104
Germany	(A/Munich/INS541/2011(H1N1))	R299K V344M I354L N456S	V845I	-	P224S N321K I330V M548I	P100S D114N P200S S202T S220T I338V E391K S468N	V100I	V106I V241I N248D K260R H275Y I321V N369K	V801		1123V		20110218
Canada	(A/Canada- AB/RV2828/2009(H1N1))		M92V N158S	-	P224S	P100S P200S S220T T258I I338V		V106I N248D H275Y V394I					20090804
USA	(A/Texas/33/2012(H1N1))				-	S86T P100S S160G P200S S202T A214T S220T N277D I338V E391K S468N V537A	-	G41R N44S V108I L127W V241I N248D H275Y N389K	V801	S13N	-	-	20120312
USA	(A/Texas/48/2012(H1N1))		-	-		S88T P100S S160G P200S S202T A214T S220T N277D I338V E391K S468N V537A	-	G41R N44S S95N V108I V241I N248D H275Y N389K	V801	S13N	-	-	20120316
United Kingdom	(A/England/00380020/2009(H1N1))		-	-	-	P100S P200S S220T 1338V	-	V106I N248D H275Y E462K	-	-	-	-	20091120
USA	(A/North Carolina/59/2009(H1N1))	-	-	-	-	P100S V169I P200S S220T P288Q I312V I338V	-	V108I V234I N248D H275Y		P25T	-	-	20091107
Spain	(A/Catalonia/NS7362/2009(H1N1))	-	-	-	-	P100S S179N P200S S220T T249A I338V G411D	-	V106I N248D H275Y	1.1	-	-	-	20091128
	A	s seen in resolve , the NA position	ed structures	of pr	ng drug resistance oteins from · mutation is invol	ad mutation rep		le for archiving or import to Exc	el		Reduced se	nsitivi	ty or resistance!
		See all inter	ractions for t	his po	sition			Mutation statistics fo	r NA at	nosition	275		

Based on FoldX structural stability calculations H275Y is predicted to be strongly destabilizing which could represent a fitness disadvantage (ddG = 4.55 kcal/mol)


PubMed search for this mutation (including alternative numbering)


stitute (<u>BII)</u>, Singapore ina Genomica (<u>INMEGEN)</u>, Mexico

utation statistics for NA at position 275 AA # Occ. % Geo Distribution Co-occurrences 0.10 2.48 197 (aeo) (co-occur) 0.16 13 н 7740 97.26 reference aa reference as ALL 7958 100.00 Sequences were compared to reference strain A/California/07/2009(H1N1) AGM53851. Last updated on Sep 02nd 2013 by Raphael Tze Chuen Lee

> Above are the occurrences of all amino acid residues at position 275 in NA. For statistics of all position in NA in this subtype click here: <u>H1N1\_NA\_mutations\_table</u>


Check for co-occurring mutations!






Check for structural interactions!


### New drug sensitivity altering mutation NA S247N



Global occurrence of new variant



Structural context of mutation




Phylogenetic context of new variant

Found circulating in 10% of samples in Singapore and 30% of samples in Northern Australia in early 2011.

Experimentally measured increase of IC50 for Tamiflu by 6-fold and Relenza by 3-fold but **normally administered dose of drugs still sufficient.** 


Collaboration between Bioinformatics Institute, A\*STAR with NPHL/Ministry of Health Singapore and WHO Collaborating Centre for Reference and Research on Influenza.

Euro Surveill. 2011;16(23):pii=19884.




Check for stability or passage effect (if available)!


### Frequency rise points to role of permissive mutations




Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. *Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.* J Infect Dis. 2012 Jul 15;206(2):148-57.

#### Current H3N2 strains have HA passage bias mutations in antigenic sites








### FluSurver – an online tool to make sequence analysis and

mutati	•	-		· · /·		tation easier
		Sum	nmary of cr	itical drug sensitivity po	sitions	
1	Residue	Туре	Ref.num.	Effect annotation	Close to drug in 3D structure (<5A)	r.
	V116	wt	116 (N2)	sensitive	· ·	x
	R118	wt	118 (N2)	no known effect (common wildtype AA)	<u>3D</u>	Check drug
	E119	wt	119 (N2)	sensitive	<u>3D</u>	
	L134	wt	134 (N2)	no known effect (common wildtype AA)	<u>3D</u>	summary table!
por	Q136	wt	136 (N2)	sensitive		
	D151	wt	151 (N2)	sensitive	<u>3D</u>	
	Y155	wt	155 (N2)	sensitive	-	
The main application scenario for FluSurver is to h	R156	wt	156 (N2)	no known effect (common wildtype AA)	<u>3D</u>	the research and should ideally be combined with experimental testing
and verification of any predicted phenotypes. Impor Our curated reference sequences used for annotatic fruitful and reliable results are current surve	S180	wt	179 (N2)	no known effect (common wildtype AA)	<u>3D</u>	or treatment should not be based solely on these computational predictions. fected humans. Therefore, the usage scenario that will give the most ng some candidates for avian flu and novel reassortant swine flu
H3N2v. Please take a look at the Free	1223	wt	222 (N2)	sensitive	<u>3D</u>	a special note for using FluSurver results in publications.
	L224	wt	223 (N2)	no known effect (common wildtype AA)	<u>3D</u>	Mr
Known effect(s) of mutations at position equivalent to	R225	wt	224 (N2)	sensitive	<u>3D</u>	nce Selection
your mutation:	T226	wt	225 (N2)	no known effect (common wildtype AA)	<u>3D</u>	
Protein: NA	Q227	wt	226 (N2)	sensitive	-	ge # mutations List of mutations
Influenza type: Human H1N1 (2006)	E228	wt	227 (N2)	sensitive	<u>3D</u>	
Mutation (as in paper): H274Y neutral AA: H	G245	wt	244 (N2)	no known effect (common wildtype AA)	<u>3D</u>	V106I, N248D, H275Y
neg. eff. AA: Y	P246	wt	245 (N2)	no known effect (common wildtype AA)	<u>3D</u>	show in structure
Effect: strong and resistance (drug name in comments)	524	wt	246 (N2)	sensitive	<u>3D</u>	NA drug sensitivity positions:
Comment:	N248D	mt	247 (N2)	no known effect (mt)	<u>3D</u>	<u>26, 0, 1</u>
Tamiflu but not Relenza resistance (Table 3)	H275Y	mt	274 (N2)	effect	<u>3D</u>	Reduced sensitivity or resistance!
Literature reference (Mutation H214Y in the paper is at an equivalent position of the	E277	wt	276 (N2)	sensitive	<u>3D</u>	pr import to Excel
mutation in you query)	R293	wt	292 (N2)	sensitive	<u>3D</u>	
	N344	wt	347 (N2)	no known effect (common wildtype AA)	<u>3D</u>	
	G345	wt	348 (N2)	no known effect (common wildtype AA)	<u>3D</u>	
S NCBI Resources THow To The Notice of the N	G348	wt	351 (N2)	no known effect (common wildtype AA)	<u>3D</u>	
US National Library of Medicine Advanced	R368	wt	371 (N2)	sensitive	<u>3D</u>	
National Institutes of Health 2011 Display Settings: © Abstract	G401	wt	405 (N2)	no known effect (common wildtype AA)	<u>3D</u>	
Antmiroch Agents Chemother, 2008 Sep, 52(9) 3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14. Surveillance for neuraminidase inhibitor resistance among human influenza A anc worldwide from 2004 to 2008. Sheu TG, Devel 4M, Quom-Ahimato M, Gaine RJ, Yuj X, Brinh RA, Butler EN, Wallis TR, Kilmov AJ, Gubareva LV Influenza Division, National Center for Immurization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlan	re positions Vicinity imply a expe specific read the	sistanc /mutatio / of a m n effect rimental subtyp annota	e but should ons that may utation to the t on the drug testing. Mos bes and may tion carefully e whether a	s not suitable to unambigous rather serve to help select have an effect for further e drug in 3D structures does and requires further carefi to fthe available effect ann hence not apply exactly to v and follow up the provided similar effect on drug sens may be plausible.	ing candidate experimental testing. s not automatically ul modelling and/or totations refer to your query. Please d links to the original	June 2 March 12 March 12

### Also useful for analysis of other segments!







### Summary of FluSurver features 2014




27



### **Analysis – FluSurver for Mutation Interpretation**





Important disclaimer:

FluSurver makes it very easy to link mutations with prior literature and potential phenotypic effects.

While we have placed great emphasis on avoiding false positive alerts and provide tutorials, one still needs to read the associated papers and interpret the provided evidence carefully to judge any effect realistically.


### FluSurver Acknowledgements

Many current and former (\*) colleagues from the A\*STAR Bioinformatics Institute (BII) contribute(d) critically to its development and maintenance, including:

**Sebastian Maurer-Stroh**, Raphael Tze Chuen Lee, Vachiranee Limviphuvadh, Jianmin Ma, Fernanda L Sirota, Vithiagaran Gunalan, Swe Swe Thet Paing\*, Narumol Doungpan\*, Joy Xiang\* and Frank Eisenhaber.

The FluSurver would be nothing without the valuable feedback and interaction with the influenza research and surveillance community, including especially and in chronological order:

- Genome Institute of Singapore (GIS), Singapore
- INMEGEN Mexico City, Mexico
- National Public Health Laboratory (NPHL) of the Ministry of Health, Singapore
- IAL Sao Paulo, Brazil
- WHO Collaborating Centre for Reference and Research on Influenza, Australia
- Duke-NUS Emerging Infectious Disease
  Programme, Singapore
- University of Melbourne, Australia
- Global Initiative for Sharing All Influenza Data (GISAID)



Contact: flusurver@gisaid.org



Fishing for Flu Mutations since 2009!

